Clinical significance of the epidermal growth factor receptor and HER2 receptor in resectable gastric cancer
Clinical significance of the epidermal growth factor receptor and HER2 receptor in resectable gastric cancer
复制标题
DOI：
10.1245/aso.2003.05.010
复制
发表时间：
2003-04-01
影响因子：
3.7
通讯作者：
García-Muñiz, JL
中科院分区：
文献类型：
--
作者：
García, I;Vizoso, F;García-Muñiz, JL
背景：表皮生长因子受体（EGFR或HER1）及其同源物c-erbB-2 （HER2）是膜受体。EGFR和HER2基因在多种实体人类癌症中均过表达，并与患者预后不良有关。本研究的目的是评估可切除胃癌中EGFR和HER2的含量及其与肿瘤临床病理参数的可能关系及其预后意义。方法：对63例可切除胃癌患者进行前瞻性分析，平均随访时间为40.7个月。膜性EGFR水平用放射配体结合法检测，胞质HER2水平用免疫酶法检测。结果：肿瘤中EGFR （1-1,239 fmol/mg蛋白）和HER2 （7-20,863 NHU/mg蛋白）水平具有广泛的可变性。这些水平与患者或肿瘤特征之间没有显著相关性。然而，高水平的EGFR和HER2与较短的总生存期显著相关（P = 0.03和P = 0.02）。结论：胃癌中膜性EGFR水平和细胞质HER2水平存在广泛的变异性，这似乎与这些肿瘤的生物学异质性有关。此外，高肿瘤EGFR和HER2水平与可切除胃癌患者的不良预后相关。
Background: Epidermal growth factor receptor (EGFR or HER1) and its homolog c-erbB-2 (HER2) are membrane receptors. Both EGFR and HER2 genes are overexpressed in a variety of solid human cancers and are related to poor prognosis of the patients. The objective of this work was to evaluate the EGFR and HER2 contents in resectable gastric cancer, their possible relationship with clinicopathologic parameters of tumors, and their prognostic significance.Methods: This was a prospective analysis of 63 patients with resectable gastric carcinomas, with a mean follow-up period of 40.7 months. Membranous EGFR levels were examined by radioligand binding assays, and cytosolic HER2 levels were examined by means of an immunoenzymatic assay.Results: There was a wide variability of EGFR (1-1,239 fmol/mg of protein) and HER2 (7-20,863 NHU/mg of protein) levels in tumors. There was no significant correlation between these levels and patient or tumor characteristics. However, high levels of EGFR and HER2 were significantly associated with a shorter overall survival period (P = .03 and P = .02, respectively).Conclusions: There is a wide variability in membranous EGFR levels and in cytosolic HER2 levels in gastric cancer, which seems to be related to the biological heterogeneity of these tumors. In addition, high tumor EGFR and HER2 levels were associated with an unfavorable outcome in patients with resectable gastric cancer.